Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Fenebrutinib in Relapsing MS: FENhance Trial Results Explained
-
Lu par :
-
De :
À propos de ce contenu audio
New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis.
In this exclusive episode, leading experts Prof. Ludwig Kappos from University of Basel and Dr. Jiwon Oh from Barlo MS Centre join host Brett Drummond to unpack the full FENhance 1 & 2 trial results.
Together, they explore:
- How fenebrutinib performed against teriflunomide in relapsing MS
- Why BTK inhibition continues to generate strong interest across the MS treatment landscape
- What the results reveal about relapse reduction, MRI outcomes, and disability progression
- What the safety profile of fenebrutinib looked like in this cohort of patients
Listen for a deep dive into the science, clinical context, and future implications for MS care.
adbl_web_anon_alc_button_suppression_c
Aucun commentaire pour le moment
